Please wait

SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* Blumberg Richard P. (Last) (First) (Middle) 5835 PEACHTREE CORNERS EAST SUITE B (Street) PEACHTREE CORNERS GA 30092 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol GUIDED THERAPEUTICS INC [ GTHP ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 02/25/2026
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/25/2026		M		1,000,000	A	(1)	8,924,180	D
Common Stock	03/26/2026		J(4)		56,093	A	(4)	8,980,273	D
Preferred Series F Stock	03/26/2026		J(5)		260	D	(5)	0	D
Common Stock	03/26/2026		J(5)		1,040,000	A	(5)	10,020,273	D
Common Stock	03/26/2026		J(6)		19,038	A	(6)	10,039,311	D
Preferred Series F-2 Stock	03/26/2026		J(7)		88	D	(7)	0	D
Common Stock	03/26/2026		J(7)		352,000	A	(7)	10,391,311	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	$0.65	02/25/2026		D(1)			1,000,000	09/01/2022	09/01/2026	Common Stock	1,000,000	(1)	0	D
Warrants	$0.65	02/25/2026		A(1)		1,000,000		02/25/2026	09/01/2027	Common Stock	1,000,000	(1)	1,000,000	D
Warrants	$0.5	02/25/2026		D(1)			1,000,000	09/01/2022	09/01/2026	Common Stock	1,000,000	(1)	0	D
Warrants	$0.2	02/25/2026		A(1)		1,000,000		02/25/2026	02/25/2026	Common Stock	1,000,000	(1)	1,000,000	D
Warrants	$0.2	02/25/2026		M(1)			1,000,000	02/25/2026	02/25/2026	Common Stock	1,000,000	$0.2(1)	0	D
Warrants	$0.3	03/01/2026		H(2)			900,000	03/01/2023	03/01/2026	Common Stock	900,000	$0.3	2,700,000	D
Stock Options	$0.29	03/10/2026		A		110,000		(3)	03/09/2036	Common Stock	110,000	$0.00	110,000	D

Explanation of Responses:

1. During February 2026, Mr. Blumberg entered into an exchange agreement pursuant to which 1,000,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 1,000,000 warrants with an exercise price of $0.20. The newly issued warrants were immediately exercised upon payment of $200,000. In connection with the exchange agreement, the expiration date of 1,000,000 warrants with an exercise price of $0.65 was extended for one year, until September 1, 2027.

2. 900,000 warrants to purchase shares of common stock with an exercise price of $0.30, with an issuance date of March 1, 2023, expired on March 1, 2026, without being exercised.

3. One-fourth of the shares subject to the award vested on March 10, 2026; the remaining shares will vest monthly, starting on June 10, 2026, subject to the reporting person's continued service on each such date, until the award is fully vested on March 10, 2029.

4. These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.2773.

5. On March 26, 2026, Mr. Blumberg converted 260 shares of Series F preferred stock into 1,040,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price.

6. These shares were issued for payment of accrued dividends on the reporting individual's Series F-2 preferred stock, at a conversion price of $0.2773.

7. On March 26, 2026, Mr. Blumberg converted 88 shares of Series F-2 preferred stock into 352,000 shares of common stock. The Series F-2 preferred stock had a stated value of $1,000 and $0.25 conversion price.

	/s/ Richard P. Blumberg	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.